Dyne Therapeutics Financial Ratios
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.64+0.27 (+1.65%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dyne Therapeutics ratio analysis
Return on equity reached -45.9%, meaning Dyne Therapeutics generated -0.46 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.15 versus 0.00 the year before, and the current ratio was 22.25. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Dyne Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / book | — | — | — | — | 1.64 | 0.88 | — |
| Return on equity (ROE) | -45.9% | -50.4% | -258.4% | -66.6% | -40.5% | -17.4% | -105.9% |
| Return on assets (ROA) | -37.6% | -45.9% | -142.9% | -54.9% | -35.1% | -16.8% | -90.4% |
| Debt / equity | 0.15 | 0.00 | — | — | — | — | — |
| Current ratio | 22.25 | 15.60 | 2.53 | 9.46 | 13.31 | 31.83 | 6.26 |